RTP Mobile Logo
Select Publications

Ades L et al. Enasidenib (ENA) is effective in patients with IDH2 mutated myelodysplastic syndrome (MDS): The ideal phase 2 study by the GFM Group. ASH 2021;Abstract 63.

Bernard E et al. Molecular International Prognosis Scoring System for myelodysplastic syndromes. ASH 2021;Abstract 61.

Brunner AM et al. Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high/high-risk myelodysplastic syndrome (vHR/HR-MDS) and acute myeloid leukemia (AML): Final analysis from a phase Ib study. ASH 2021;Abstract 244.

Chen S et al. Venetoclax plus decitabine for young adults with newly diagnosed ELN adverse-risk acute myeloid leukemia: Interim analysis of a prospective, multicenter, single-arm, phase 2 trial. ASH 2021;Abstract 35.

Daver N et al. Phase I/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (magro) in patients (pts) with newly diagnosed older/unfit or high-risk acute myeloid leukemia (AML) and relapsed/refractory (R/R) AML. ASH 2021;Abstract 371.

Garcia JS et al. Molecular responses are observed across mutational spectrum in treatment-naïve higher-risk myelodysplastic syndrome patients treated with venetoclax plus azacitidine. ASH 2021;Abstract 241.

Garcia-Manero G et al. Oral decitabine/cedazuridine in patients with lower risk myelodysplastic syndrome: A longer-term follow-up of from the ASCERTAIN study. ASH 2021;Abstract 66.

Grenet J et al. Comparing outcomes between liposomal daunorubicin/cytarabine (CPX-351) and HMA+venetoclax as frontline therapy in acute myeloid leukemia. ASH 2021;Abstract 32.

Jacoby MA et al. A pilot study of CPX-351 for transplant eligible, higher risk patients with myelodysplastic syndrome. ASH 2021;Abstract 540.

Komrokji RS et al. Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndromes. ASH 2021;Abstract 536.

Lachowiez C et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. ASH 2021;Abstract 701.

Montesinos P et al. AGILE: A global, randomized, double-blind, phase 3 study of ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation. ASH 2021;Abstract 697.

Peterlin P et al. CPX 351 as first line treatment in higher risk MDS. A phase II trial by the GFM. ASH 2021;Abstract 243.

Pollyea DA et al. Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax combined with hypomethylating agents. ASH 2021;Abstract 224.

Sebert M et al. Ivosidenib monotherapy is effective in patients with IDH1 mutated myelodysplastic syndrome (MDS): The IDIOME phase 2 study by the GFM Group. ASH 2021;Abstract 62.

Short NJ et al. A triplet combination of azacitidine, venetoclax and gilteritinib for patients with FLT3-mutated acute myeloid leukemia: Results from a phase I/II study. ASH 2021;Abstract 696.

Wang ES et al. Phase 3, open-label, randomized study of gilteritinib and azacitidine vs azacitidine for newly diagnosed FLT3-mutated acute myeloid leukemia in patients ineligible for intensive induction chemotherapy. ASH 2021;Abstract 700.

Wang J et al. Gilteritinib versus salvage chemotherapy for relapsed/refractory FLT3-mutated acute myeloid leukemia: A phase 3, randomized, multicenter, open-label trial in Asia. ASH 2021;Abstract 695.

Yilmaz M et al. Quizartinib (quiz) with decitabine (dac) and venetoclax (ven) is highly active in patients (pts) with FLT3-ITD mutated acute myeloid leukemia (AML) – RAS/MAPK mutations continue to drive primary and secondary resistance. ASH 2021;Abstract 370.